Search - tctmd.com

Displaying 61 - 80 of 3208

Sort: Relevancy | Date

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Case Introduction: An Elderly Patient With NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Alberto Menozzi

November 01, 2016

Presentation TCT 2016

Case Presentation: ACS Intervention in the Emerging BRS Era

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Evgeny V. Merkulov

November 01, 2016

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation TCT 2016

Very Long Term Outcomes after FFR-Based Decision-Making

Presenter: Nick Curzen, Nils Johnson, Frederik M. Zimmermann

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

iFR in Acute Coronary Syndromes

Presenter: Nick Curzen, Nils Johnson, Justin E. Davies

November 01, 2016

Presentation TCT 2016

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

Presenter: Jonathan M. Hill, Christoph K. Naber, Manel Sabate

November 01, 2016

Presentation TCT 2016

Delivery System and Therapeutic Challenges and Opportunities in Africa

Presenter: Graham A. Cassel, Harun A Otieno

November 01, 2016

Presentation TCT 2016

FFR in ACS: Current Data Including DOCTORS and Upcoming Studies

Presenter: Nick Curzen, Nils Johnson, Thomas Engstroem

November 01, 2016

Presentation TCT 2016

FFR in ACS: Specifics and Timing of Measurements

Presenter: Nick Curzen, Nils Johnson, Habib Samady

November 01, 2016

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Advertisement

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

To Pretreat or Not to Pretreat? The DUBIUS Trial

Case Introduction: An Elderly Patient With NSTE-ACS

Case Presentation: ACS Intervention in the Emerging BRS Era

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Very Long Term Outcomes after FFR-Based Decision-Making

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

iFR in Acute Coronary Syndromes

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

Delivery System and Therapeutic Challenges and Opportunities in Africa

FFR in ACS: Current Data Including DOCTORS and Upcoming Studies

FFR in ACS: Specifics and Timing of Measurements

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content